drugset / Trial / NCT03890198
A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma
Phase 0
Terminated
2 enrolled
First Affiliated Hospital Xi'an Jiaotong University
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single center, single arm phase 1 study to evaluate the safety , tolerability, pharmacokinetics and efficacy and immunogenicity of LCAR-C182A cells targeting Claudin18.2 in the treatment of patients with advanced gastric cancer and Pancreatic Ductal Adenocarcinoma.
Timeline
- Start
- 2019-04-22
- Primary completion
- 2020-03-06
- Completion
- 2020-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCAR-C182A cells | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 30 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 300 mg/m2 | Intravenous |